^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CYP11B1 rs4736349

    i
    Other names: CYP11B1, Cytochrome P450 Family 11 Subfamily B Member 1, P450C11, CPN1, FHI, Cytochrome P450, Subfamily XIB (Steroid 11-Beta-Hydroxylase), Polypeptide 1, Cytochrome P450, Family 11, Subfamily B, Polypeptide 1, Steroid 11-Beta-Hydroxylase, CYP11B1, Cytochrome P450 11B1, Mitochondrial, Steroid 11-Beta-Monooxygenase, Cytochrome P-450c11, Cytochrome P450C11, CYP11B, Cytochrome P450 XIB1, CYPXIB1, S11BH
    Entrez ID:
    1584
    2years
    A common germline variant in CYP11B1 is associated with adverse clinical outcome of treatment with abiraterone or enzalutamide. (PubMed, Biomed Pharmacother)
    The frequent germline variant rs4736349 in CYP11B1 is, as homozygote, an independent negative prognostic factor for treatment with abiraterone or enzalutamide in ARSi naive metastatic prostate cancer patients. Our findings warrant prospective investigation of this potentially important predictive biomarker.
    Clinical data • Journal • Adverse events
    |
    CYP17A1 (Cytochrome P450 Family 17 Subfamily A Member 1) • HSD3B1 (Hydroxy-Delta-5-Steroid Dehydrogenase 3 Beta- And Steroid Delta-Isomerase 1) • SRD5A1 (Steroid 5 Alpha-Reductase 1) • SRD5A2 (Steroid 5 Alpha-Reductase 2)
    |
    CYP11B1 rs4736349
    |
    Xtandi (enzalutamide) • abiraterone acetate